entertainment -WSS

entertainment

author：comprehensive 2025-09-29 01:38:45 - browse：78

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

WSS

Trump got a 'target letter.' What is one and what does it mean?

As JPM 2024 winds down, some health tech firms project optimism

How dance can help health care workers heal from trauma

Couple fighting to bring baby home from Mexico are finally reunited

Researchers separate signal from noise in heart wearable data

India sets sights on home

leisure time

entertainment

entertainment

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Caregivers of transplant patients call for more support, training

Wildfire smoke exposes gaps in outdoor worker protections

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

States increasingly look to regulate hospital facility fees

Psychedelics group wrestles with new pharma identity

Researchers separate signal from noise in heart wearable data

Hollywood unions extend contract negotiations for actors

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

focus

Suspected Gilgo Beach killer appeared 'traumatized' after arrest: Defense attorney

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Health and fitness trackers are measuring the wrong things

New warning issued for rebooking air travel after delays, cancellations

DOJ, FTC to increase scrutiny of all types of health care mergers

focus

knowledge

focus

knowledge